(Total Views: 904)
Posted On: 02/01/2021 11:19:58 AM
Post# of 148903
Reddit Rebellion Targeting the Short Mafia Next
Interesting article today in Insider Financial by Chris Sandberg.
https://insiderfinancial.com/reddit-rebellion...xt/180939/
He showed an updated org chart of The Short Mafia with Andrew Left and Tim Sykes crossed out. He thinks the next 3 nails in Feuerstein's coffin will be CytoDyn, Cel-Sci, and Northwest Biotech in that order. He wrote this about CYDY:
TOP TARGET – CYTODYN
CytoDyn has one of the sexiest stories on the street. Friday, after the bell the company announced the initiation of sales in the Philippines. For years the shorts have been clamoring about no revenue and it looks like CytoDyn’s CEO finally took away their favorite piece of candy. This was only one part of the news, the other part was the shocking announcement that 100,000 doses of the drug was to be reserved for the Philippines and their partner Chiral Pharma Corp. The Manilla Times picked up on the story. There are currently only 250,000 doses ready to be shipped out of Samsung South Korea. This news puts the United States FDA in a pressure situation to approve the drug. In a webinar last week some of the country’s top doctors and regulators in the Philippines were educated on the Compassionate Special Permit (CSP) for leronlimab. CytoDyn also hinted that this was a stepping stone to an EUA and ultimately an approval in the philippines. The idea is that these compassionate use patients would fit the CD12 enrollment criteria for the extension trial and help get more data on the drug. The CEO Nader Pourhassen said
“The MHRA in the UK already asked us to immediately send the results to them. The head of the FDA in the United States requested to see the data as soon as it is unblinded without waiting for the top line report. They are very eager to get this.”
New investors to CYDY should realize how high the probability of approval is. The two major questions the FDA asks. Is it safe and does it work? The safety question is a resounding yes, because over 1000 patients have taken it without even one Severe Adverse Event (SAE). Efficacy is likely to be a blowout too because the Drug Safety Monitoring Committee (DSMC) looked at the study 3 times and each and every time they said to continue the study and that it was likely to meet its mortality endpoint of 28 day all cause mortality. There hasn’t even been one study in COVID-19 that has finished the clinical trial with their mortality endpoint intact. This is such an important point because even if they fail in a worst case scenario they are likely to get approval on one of the secondary endpoints.
Interesting article today in Insider Financial by Chris Sandberg.
https://insiderfinancial.com/reddit-rebellion...xt/180939/
He showed an updated org chart of The Short Mafia with Andrew Left and Tim Sykes crossed out. He thinks the next 3 nails in Feuerstein's coffin will be CytoDyn, Cel-Sci, and Northwest Biotech in that order. He wrote this about CYDY:
TOP TARGET – CYTODYN
CytoDyn has one of the sexiest stories on the street. Friday, after the bell the company announced the initiation of sales in the Philippines. For years the shorts have been clamoring about no revenue and it looks like CytoDyn’s CEO finally took away their favorite piece of candy. This was only one part of the news, the other part was the shocking announcement that 100,000 doses of the drug was to be reserved for the Philippines and their partner Chiral Pharma Corp. The Manilla Times picked up on the story. There are currently only 250,000 doses ready to be shipped out of Samsung South Korea. This news puts the United States FDA in a pressure situation to approve the drug. In a webinar last week some of the country’s top doctors and regulators in the Philippines were educated on the Compassionate Special Permit (CSP) for leronlimab. CytoDyn also hinted that this was a stepping stone to an EUA and ultimately an approval in the philippines. The idea is that these compassionate use patients would fit the CD12 enrollment criteria for the extension trial and help get more data on the drug. The CEO Nader Pourhassen said
“The MHRA in the UK already asked us to immediately send the results to them. The head of the FDA in the United States requested to see the data as soon as it is unblinded without waiting for the top line report. They are very eager to get this.”
New investors to CYDY should realize how high the probability of approval is. The two major questions the FDA asks. Is it safe and does it work? The safety question is a resounding yes, because over 1000 patients have taken it without even one Severe Adverse Event (SAE). Efficacy is likely to be a blowout too because the Drug Safety Monitoring Committee (DSMC) looked at the study 3 times and each and every time they said to continue the study and that it was likely to meet its mortality endpoint of 28 day all cause mortality. There hasn’t even been one study in COVID-19 that has finished the clinical trial with their mortality endpoint intact. This is such an important point because even if they fail in a worst case scenario they are likely to get approval on one of the secondary endpoints.
(15)
(0)Scroll down for more posts ▼
